Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JATT II Acquisition Corp.JATT · Entity 6799 | Director · Chief Executive Officer · 10% owner | June 06, 2026 | June 30, 2026 |
| JATT III Acquisition CorpJTTT · Entity 6795 | Director · CEO and Chairman · 10% owner | August 27, 2026 | August 27, 2026 |
| Zura Bio LtdZURA · Entity 5413 | Director | May 21, 2025 | May 22, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JATT II Acquisition Corp.
Report date June 06, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 1,800,000 |
Reported balance
After 2026-06-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-06 · Other · Disposed 225,000 · Balance 1,800,000 F1: 225,000 Ordinary Shares were forfeited to the Issuer by JATT Ventures II L.P. (the "Sponsor") at no cost, in connection with the expiration of the remaining portion of the underwriters' over-allotment option as described in the Registration Statement. F2: The Sponsor is the record holder of the securities reported herein. The Sponsor is the sole general partner of JATT Ventures II L.P., and Dr. Someit Sidhu is a limited partner of the Sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
Filing footnotes · ownership attribution and instrument terms
F1: 225,000 Ordinary Shares were forfeited to the Issuer by JATT Ventures II L.P. (the "Sponsor") at no cost, in connection with the expiration of the remaining portion of the underwriters' over-allotment option as described in the Registration Statement.
F2: The Sponsor is the record holder of the securities reported herein. The Sponsor is the sole general partner of JATT Ventures II L.P., and Dr. Someit Sidhu is a limited partner of the Sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
JATT III Acquisition Corp
Report date August 27, 2026 · Filed August 27, 2026
Jointly reported with JATT Ventures III L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,959,000 |
Reported balance
After 2026-08-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-27 · Purchase · Acquired 234,000 · Balance 1,959,000 F1: Reflects the 234,000 private placement shares purchased by JATT Ventures III L.P., the Issuer's sponsor (the "Sponsor") of its initial public offering, pursuant to the Private Placement Shares Purchase Agreement dated August 25, 2026 by and between the Issuer and the Sponsor. F2: The Sponsor is the record holder of the securities reported herein. JATT Ventures III Ltd is the sole general partner of the Sponsor, and Dr. Someit Sidhu is a limited partner of the Sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures III Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the 234,000 private placement shares purchased by JATT Ventures III L.P., the Issuer's sponsor (the "Sponsor") of its initial public offering, pursuant to the Private Placement Shares Purchase Agreement dated August 25, 2026 by and between the Issuer and the Sponsor.
F2: The Sponsor is the record holder of the securities reported herein. JATT Ventures III Ltd is the sole general partner of the Sponsor, and Dr. Someit Sidhu is a limited partner of the Sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures III Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
Zura Bio Ltd
Report date May 21, 2025 · Filed May 22, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2035-05-21 | Direct | 51,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 51,000 · Balance 51,000 F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 27, 2026 Filed Aug 27, 2026 22:02 UTC | JATT III Acquisition Corp JTTT · Entity 6795 | PurchaseOrdinary Shares | 234,000 | $10.00 | $2,340,000.00 |
DisclosureSEC source: 0001213900-26-094460 · ownership.xml · nonDerivative · entry 1 JATT Ventures III L.P. · CIK 0002150876 · 10% owner Sidhu Someit · CIK 0001870329 · Director · CEO and Chairman · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,959,000 F1 · kind: Reflects the 234,000 private placement shares purchased by JATT Ventures III L.P., the Issuer's sponsor (the "Sponsor") of its initial public offering, pursuant to the Private Placement Shares Purchase Agreement dated August 25, 2026 by and between the Issuer and the Sponsor. F2 · balance_after: The Sponsor is the record holder of the securities reported herein. JATT Ventures III Ltd is the sole general partner of the Sponsor, and Dr. Someit Sidhu is a limited partner of the Sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures III Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document |
| June 06, 2026 Filed Jun 30, 2026 21:11 UTC | JATT II Acquisition Corp. JATT · Entity 6799 | OtherOrdinary Shares | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-073806 · ownership.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,800,000 F1 · kind: 225,000 Ordinary Shares were forfeited to the Issuer by JATT Ventures II L.P. (the "Sponsor") at no cost, in connection with the expiration of the remaining portion of the underwriters' over-allotment option as described in the Registration Statement. F1 · shares: 225,000 Ordinary Shares were forfeited to the Issuer by JATT Ventures II L.P. (the "Sponsor") at no cost, in connection with the expiration of the remaining portion of the underwriters' over-allotment option as described in the Registration Statement. F2 · balance_after: The Sponsor is the record holder of the securities reported herein. The Sponsor is the sole general partner of JATT Ventures II L.P., and Dr. Someit Sidhu is a limited partner of the Sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. F2 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Sponsor is the sole general partner of JATT Ventures II L.P., and Dr. Someit Sidhu is a limited partner of the Sponsor. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by the Sponsor. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 21:37 UTC | JATT II Acquisition Corp. JATT · Entity 6799 | PurchaseOrdinary shares | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-046288 · ownership.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,025,000 F1 · kind: Reflects the 300,000 private placement shares purchased by JATT Ventures II L.P., the Issuer's sponsor, pursuant to the Private Placement Shares Purchase Agreement dated April 16, 2026 entered into with the Issuer. F1 · price: Reflects the 300,000 private placement shares purchased by JATT Ventures II L.P., the Issuer's sponsor, pursuant to the Private Placement Shares Purchase Agreement dated April 16, 2026 entered into with the Issuer. F2 · balance_after: Including up to 225,000 Ordinary Shares subject to forfeiture depending on the extent to which the Issuer's underwriter' over-allotment option was exercised during the Issuer's initial public offering. JATT Ventures II L.P. is the record holder of the securities reported herein. JATT Ventures II Ltd is the sole general partner of JATT Ventures II L.P., and Dr. Someit Sidhu is a limited partner of JATT Ventures II L.P.. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by JATT Ventures II L.P. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by JATT Ventures II L.P. other than to the extent of any pecuniary interest he may have therein, directly or indirectly. F2 · ownership.nature: Including up to 225,000 Ordinary Shares subject to forfeiture depending on the extent to which the Issuer's underwriter' over-allotment option was exercised during the Issuer's initial public offering. JATT Ventures II L.P. is the record holder of the securities reported herein. JATT Ventures II Ltd is the sole general partner of JATT Ventures II L.P., and Dr. Someit Sidhu is a limited partner of JATT Ventures II L.P.. Dr. Someit Sidhu is also the sole member of JATT Ventures II Ltd. Dr. Someit Sidhu has voting and investment discretion with respect to the ordinary shares held of record by JATT Ventures II L.P. Dr. Someit Sidhu disclaims any beneficial ownership of the securities held by JATT Ventures II L.P. other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:38 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001415889-25-014225 · form4-05222025_090527.xml · derivative · entry 1 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:45 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028972 · form4-12112024_041203.xml · derivative · entry 1 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Class A Ordinary Shares · 117,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 21:37 UTC | Zura Bio Ltd ZURA · Entity 5413 | SaleClass A ordinary shares | 51,728 | $3.87 | $200,187.36 |
DisclosureSEC source: 0001415889-24-023032 · form4-09062024_090904.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,085,418 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.86 to $3.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 04, 2024 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherClass A Ordinary Shares | 593,055 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · nonDerivative · entry 6 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 242,055 F4 · kind: JATT transferred Class A ordinary shares to Willow Gate, LLC for no additional consideration. F4 · price: JATT transferred Class A ordinary shares to Willow Gate, LLC for no additional consideration. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| August 24, 2024 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantClass A Ordinary Shares | 721,971 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · nonDerivative · entry 5 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,807,389 F5 · kind: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F5 · price: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. Read SEC document |
| August 24, 2024 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantClass A Ordinary Shares | 835,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · nonDerivative · entry 4 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 242,055 F5 · kind: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F5 · price: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| August 23, 2024 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | Disposition to issuerWarrants · Derivative | 2,406,573 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · derivative · entry 14 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,406,573 shares Expires 2028-03-20 F5 · kind: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F5 · price: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F5 · derivative.underlying_shares: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. Read SEC document |
| August 23, 2024 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | Disposition to issuerWarrants · Derivative | 2,783,701 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · derivative · entry 13 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,783,701 shares Expires 2028-03-20 F5 · kind: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F5 · price: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F5 · derivative.underlying_shares: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 22:51 UTC | Zura Bio Ltd ZURA · Entity 5413 | PurchaseClass A ordinary shares | 1,186,901 | $3.13 | $3,715,000.13 |
DisclosureSEC source: 0001415889-24-011479 · form4-04242024_100449.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,186,901 F1 · kind: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Pegasus LLC at a purchase price of $3.13 per share. F2 · ownership.nature: These shares were acquired by Pegasus LLC. The Reporting Person is the sole member and beneficial owner of the limited liability company interests of Pegasus LLC. Read SEC document |
| April 22, 2024 Filed Sep 6, 2024 21:34 UTC Amendment | Zura Bio Ltd ZURA · Entity 5413 | GrantClass A ordinary shares | 1,186,901 | $3.13 | $3,715,000.13 |
DisclosureSEC source: 0001415889-24-023030 · form4a-09062024_090959.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LLC Disclosed balance after: 1,186,901 F1 · kind: On April 24, 2024, the Reporting Person filed a Form 4 which inadvertently included the incorrect transaction code due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'A' instead of transaction code 'P'. F2 · shares: These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Pegasus LLC at a purchase price of $3.13 per share. F3 · ownership.nature: These shares were acquired by Pegasus LLC. The Reporting Person is the sole member and beneficial owner of the limited liability company interests of Pegasus LLC. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 20:13 UTC | Zura Bio Ltd ZURA · Entity 5413 | PurchaseWarrants · Derivative | 1,750,000 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-23-125675 · tm2332812-1_4seq1.xml · derivative · entry 1 Sidhu Someit · CIK 0001870329 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,750,000 Underlying: Class A Ordinary Shares · 1,750,000 shares Expires 2028-03-20 F1 · price: The Reporting Person purchased the warrants at $0.33 per warrant pursuant to certain purchase agreement dated December 11, 2023. Read SEC document |
| November 21, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherClass A Ordinary Shares | 351,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · nonDerivative · entry 3 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 242,055 F4 · kind: JATT transferred Class A ordinary shares to Willow Gate, LLC for no additional consideration. F4 · price: JATT transferred Class A ordinary shares to Willow Gate, LLC for no additional consideration. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| October 30, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | PurchaseWarrants · Derivative | 2,480,000 | $0.25 Strike: $11.50 | $620,000.00 |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · derivative · entry 12 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 2,480,000 shares Expires 2028-03-20 F9 · price: The warrants were purchased by way of a private transaction. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| September 28, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherWarrants · Derivative | 656,573 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · derivative · entry 11 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 656,573 shares Expires 2028-03-20 F8 · kind: The warrants were distributed by JATT to the Reporting Person for no additional consideration. F8 · price: The warrants were distributed by JATT to the Reporting Person for no additional consideration. Read SEC document |
| September 28, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherWarrants · Derivative | 1,464,617 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · derivative · entry 10 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 1,464,617 shares Expires 2028-03-20 F7 · kind: JATT distributed private placement warrants to its members with no consideration being paid in connection therewith. F7 · price: JATT distributed private placement warrants to its members with no consideration being paid in connection therewith. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| September 28, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherClass A Ordinary Shares | 761,370 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · nonDerivative · entry 2 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 242,055 F2 · kind: JATT distributed Class A ordinary shares to its members with no consideration being paid in connection therewith. F2 · price: JATT distributed Class A ordinary shares to its members with no consideration being paid in connection therewith. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| September 22, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherClass A Ordinary Shares | 200,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,807,389 F1 · kind: The shares were distributed by the Reporting Person to JATT Ventures, L.P. ("JATT") directors for no additional consideration. F1 · price: The shares were distributed by the Reporting Person to JATT Ventures, L.P. ("JATT") directors for no additional consideration. Read SEC document |
| June 23, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherWarrants · Derivative | 8,216 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · derivative · entry 9 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 8,216 shares Expires 2028-03-20 F7 · kind: JATT distributed private placement warrants to its members with no consideration being paid in connection therewith. F7 · price: JATT distributed private placement warrants to its members with no consideration being paid in connection therewith. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:19 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 1,950,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001104659-23-063322 · tm2316481-11_4seq1.xml · derivative · entry 1 Sidhu Someit · CIK 0001870329 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950,000 Underlying: Class A Ordinary Shares · 1,950,000 shares Expires 2033-05-18 F1 · derivative.exercise_price: The Employee Share Option is a nil cost option granted under the Issuer's 2023 Equity Incentive Plan and the applicable UK Subplan. F2 · derivative.exercise_date: 25% of the option shall become exercisable on May 18, 2024 and a further 2.083% of it shall become exercisable at the end of each month thereafter. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 01:43 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherClass A ordinary shares | 2,337,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-035745 · tm2310290-1_4seq1.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,337,630 F1 · kind: Shares were previously Class B shares distributed by JATT Ventures, L.P. (the "JATT") to certain of its members. Such shares were transferred to the reporting person for nominal consideration due to the failure of the members to comply with the terms of the agreement under which they received membership interests in JATT. F1 · price: Shares were previously Class B shares distributed by JATT Ventures, L.P. (the "JATT") to certain of its members. Such shares were transferred to the reporting person for nominal consideration due to the failure of the members to comply with the terms of the agreement under which they received membership interests in JATT. Read SEC document |
| March 20, 2023 Filed Feb 14, 2025 21:27 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherWarrants · Derivative | 4,133,466 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004113 · form5-02142025_090247.xml · derivative · entry 8 Sidhu Someit · CIK 0001870329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By JATT Ventures, L.P. Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 4,133,466 shares Expires 2028-03-20 F7 · kind: JATT distributed private placement warrants to its members with no consideration being paid in connection therewith. F7 · price: JATT distributed private placement warrants to its members with no consideration being paid in connection therewith. F3 · ownership.nature: These securities are owned by JATT. The Reporting Person is the sole director of the sole general partner of JATT and, as such, has voting and investment discretion with respect to the ordinary shares held by JATT. The Reporting Person may be deemed to have shared beneficial ownership of the ordinary shares held directly by JATT. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 22:25 UTC | Zura Bio Ltd JATT · Entity 5413 | OtherClass B ordinary shares | 2,337,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-022452 · tm237043-1_4seq1.xml · nonDerivative · entry 1 Sidhu Someit · CIK 0001870329 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 967,370 F1 · kind: Shares were distributed by JATT Ventures, L.P. (the Sponsor") to various members. F1 · price: Shares were distributed by JATT Ventures, L.P. (the Sponsor") to various members. F2 · ownership.nature: The Shares are beneficially owned by the Sponsor. Dr. Sidhu is the sole director of JATT Ventures, Ltd., the sole general partner of the Sponsor and has voting and investment discretion with respect to the ordinary shares held by the Sponsor and may be deemed to have shared beneficial ownership of the ordinary shares held directly by the Sponsor. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.